Dhara, S.
Chhangawala, S. http://orcid.org/0000-0001-9626-1034
Chintalapudi, H.
Askan, G.
Aveson, V.
Massa, A. L. http://orcid.org/0000-0002-5888-2910
Zhang, L.
Torres, D.
Makohon-Moore, A. P. http://orcid.org/0000-0002-4781-3565
Lecomte, N.
Melchor, J. P.
Bermeo, J.
Cardenas, A. III
Sinha, S.
Glassman, D. http://orcid.org/0000-0001-5376-6526
Nicolle, R. http://orcid.org/0000-0001-8084-1173
Moffitt, R. http://orcid.org/0000-0003-2723-5902
Yu, K. H.
Leppanen, S.
Laderman, S.
Curry, B.
Gui, J.
Balachandran, V. P. http://orcid.org/0000-0002-2956-223X
Iacobuzio-Donahue, C. http://orcid.org/0000-0002-4672-3023
Chandwani, R.
Leslie, C. S. http://orcid.org/0000-0002-4571-5910
Leach, S. D.
Article History
Received: 28 September 2020
Accepted: 9 April 2021
First Online: 24 May 2021
Competing interests
: ATAC-array technology has been filed under U.S. patent PCT/US2019/046301. Patent applicants are the Trustees of Dartmouth College, 11 Rope Ferry Road, New Hampshire, 03755, US, and Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York, 10065, US. Inventors, Dhara, Surajit, Leach, Steven D., Chhangawala, Sagar, Leslie, Christina. Parts of the manuscript explaining the development of the ATAC-array technology and also the prediction of DFS (following gemcitabine adjuvant chemotherapy) by combining ATAC-array and HNF1b of this patent have been included in this patent. The international patient is published on February 20, 2020 (WO/2020/036929). Surajit Dhara and Steven D. Leach are co-founders of Episteme Prognostics; work on this project has been performed under a formal Conflict of Interest Management Plan at Dartmouth College. Steven D. Leach is also a member of the Scientific Advisory Board of Nybo Therapeutics. Other authors declare no competing interests.